Amgen: Imdelltra Data And Q1 Results Impress

Amgen reported strong Q1 2025 results, exceeding consensus EPS and revenue estimates, driven by Blincyto, Tezspire, Prolia, and particularly Imdelltra, which saw sales of $81 million, a 20.9% quarter-over-quarter increase. Furthermore, positive Phase 3 DeLLphi-304 study data for Imdelltra in treating small cell lung cancer (SCLC) was presented at ASCO. The company's dividend yield exceeds 3%, and it is actively enrolling patients in Phase 3 studies for MariTide in obesity, contributing to a continued 'buy' rating.

Analysis

Amgen reported a robust first quarter in 2025, exceeding consensus non-GAAP EPS and revenue estimates, despite challenges within its rare disease portfolio. The positive performance was primarily driven by strong sales from key products such as Blincyto, Tezspire, and Prolia, with particular strength from Imdelltra in the oncology franchise. Imdelltra generated $81 million in sales during the first three months of 2025, representing a significant 20.9% quarter-over-quarter increase. Further bolstering Imdelltra's outlook, Amgen presented impressive efficacy data from the Phase 3 DeLLphi-304 study for small cell lung cancer (SCLC) treatment at the 2025 ASCO meeting on June 2, 2025. Additionally, the company's dividend yield surpasses 3%, and it is actively progressing its potential blockbuster obesity treatment, MariTide, through Phase 3 MARITIME studies, signaling multiple growth drivers.

Key Decisions for Investors

• Investors should assess Amgen's strong Q1 2025 financial results and the significant 20.9% quarter-over-quarter sales growth of Imdelltra as key positive developments, further supported by promising Phase 3 data for SCLC.
• Ongoing monitoring of Imdelltra's sales trajectory and clinical milestones from the MariTide Phase 3 obesity studies will be critical for evaluating Amgen's growth potential and market positioning.
• While the dividend yield exceeding 3% offers an attractive income stream, continued attention should be paid to the performance of the rare disease portfolio to fully contextualize the company's overall financial health and risk profile.